遠大醫藥(00512.HK):集團全球創新產品STC3141在中國開展的II期臨牀研究成功達到臨牀終點
格隆匯5月6日丨遠大醫藥(00512.HK)發佈公告,集團全資擁有附屬公司 Grand Medical Pty Ltd.(一間本集團在澳洲設立的創新藥研發中心)開發的全球創新藥物STC3141,在中國開展的用於治療膿毒症的II期臨牀研究成功達到臨牀終點,該臨牀研究進度處於全球膿毒症研究領域前列,這是本集團在危重症領域的又一重大研發進展。同時,STC3141是全球首個以重新構建免疫穩態爲核心的膿毒症治療方案,實現了治療維度的重大升級,在現有的抗感染、液體復甦和維持器官運轉等對症支持治療的基礎上,針對機體免疫失調這個核心病因加以精準調節,幫助身體恢復平衡,填補了當前膿毒症針對病因治療的臨牀空白。這次臨牀研究的成功有望推動膿毒症治療邁入一個新紀元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.